FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
TUESDAY, Oct. 17, 2023 -- The U.S. Food and Drug Administration approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC).
The approval was based on results from the ELEVATE UC phase 3 registrational... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 17, 2023 Category: General Medicine Source Type: news
FDA Approves Velsipity (etrasimod) for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
NEW YORK--(BUSINESS WIRE) October 13, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Velsipity™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Drug for Ulcerative Colitis FDA Approves New Drug for Ulcerative Colitis
Etrasimod is the second oral sphingosine-1-phosphate (S1P) receptor approved in the US for treating moderate to severe active ulcerative colitis in adults.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 13, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news
Pfizer Wins FDA Approval for New Ulcerative Colitis Pill
The treatment, to be marketed at Velsipity, is one of a number of new products that Pfizer expects to bring in a combined $20 billion in potential annual revenue by 2030.#velsipity #pfizer (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2023 Category: Consumer Health News Source Type: news
New Oral Drug Approved for Ulcerative Colitis in Adults
(MedPage Today) -- The FDA approved oral etrasimod (Velsipity) on Friday for treating moderately to severely active ulcerative colitis (UC) in adults, drugmaker Pfizer announced.
Approval of the selective sphingosine-1-phosphate (S1P) receptor... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 13, 2023 Category: American Health Source Type: news
Monthly News Roundup - September 2023
Subcutaneous Form of Entyvio Approved for Ulcerative Colitis
In addition to the intravenous (IV) formulation, the FDA has now approved subcutaneous (SC) Entyvio (vedolizumab) for maintenance therapy in adults with moderately-to-severely active... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2023 Category: Pharmaceuticals Source Type: news
Treatment Goals for Moderately to Severely Active UC Treatment Goals for Moderately to Severely Active UC
Watch this short expert video to learn about the main treatment goals in ulcerative colitis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Including Bowel Urgency in UC Remission Indices Including Bowel Urgency in UC Remission Indices
Watch this short expert video to find out what experts think about including bowel urgency in ulcerative colitis remission indicesMedscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
U.S. FDA Approves Subcutaneous Administration of Takeda's Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 27, 2023– Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of Entyvio® (vedolizumab) for maintenance therapy in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2023 Category: Drugs & Pharmacology Source Type: news
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days
Morphic stock plummeted Monday after the company's ulcerative colitis drug underperformed a rival. MORF stock has lost 52% over two days. The post The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days appeared first on Investor's Business Daily.#morphic (Source: Reuters: Health)
Source: Reuters: Health - September 25, 2023 Category: Consumer Health News Source Type: news
NHS spending watchdog greenlights jab for patients with debilitating bowel disease ulcerative colitis
The once-a-month injection, the treatment will be offered to ulcerative colitis patients who have not responded to other treatments. It is expected to benefit about 23,000 people in England. (Source: the Mail online | Health)
Source: the Mail online | Health - September 23, 2023 Category: Consumer Health News Source Type: news
Many Young People Stop UC Maintenance Tx, Risking Relapse Many Young People Stop UC Maintenance Tx, Risking Relapse
A study finds that nearly 70% of adolescents and young adults discontinue oral 5-aminosalicylic acid within a year of ulcerative colitis diagnosis, raising their risk for relapse and complications.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 23, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
5-ASA Discontinuation Common Within First Year of Ulcerative Colitis Diagnosis in Youth
WEDNESDAY, Sept. 20, 2023 -- For adolescents and young adults diagnosed with ulcerative colitis (UC), the rate of discontinuation of 5-aminosalicylic acid (5-ASA) maintenance treatment is high within the first year, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news
Inflammatory Bowel Disease Is on the Rise in Canada Inflammatory Bowel Disease Is on the Rise in Canada
The number of people in Canada with inflammatory bowel disease (Crohn ' s disease and ulcerative colitis) will rise to 470,000, or 1.1% of the population, by 2035, according to a new report.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 13, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Higher Dietary Fiber Intake and Risk of IBD Higher Dietary Fiber Intake and Risk of IBD
This study investigated the association of dietary fiber intake from fruit, vegetable, bread, and cereal sources and incidence of IBD, Crohn ' s disease, and ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
